AC Immune SA

From Verify.Wiki
Jump to: navigation, search
AC Immune SA
Type Public
Industry Biotechnology
Founded 2003
Headquarters Lausanne, Switzerland
Key people Andrea Pfeifer (Co-Founder & CEO), Jean-Fabien Monin (CFO), Andreas Muhs (CSO) [1]
Investors Dietmar Hopp
Number of employees 62 [2]

AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. The company’s technology platforms create antibodies, small molecules, and vaccines to address a broad spectrum of neurodegenerative indications. It offers its therapies to address Alzheimer disease and neurodegenerative diseases, such as Parkinson’s, Down syndrome, and glaucoma.
AC Immune SA was founded in 2003 and is based in Lausanne, Switzerland. [3]



Top 5 Recent Tweets

September 24, 2018beyond_ninetyAC Immune SA $ACIU Forms $8.55 Double Bottom; Archon Partners Lifted By $1.27 Million Its Microsoft $MSFT Holding
September 23, 2018TranscriptDailyBrokerages Set $24.00 Price Target for AC Immune SA $ACIU
September 23, 2018stocknewstimesBrokerages Set $24.00 Target Price for AC Immune SA (ACIU)
September 22, 2018registrarjournZacks: AC Immune SA $ACIU Given Consensus Rating of “Strong Buy” by Brokerages
September 22, 2018EnterpriseLeadeZacks: AC Immune SA $ACIU Given Consensus Rating of “Strong Buy” by Brokerages

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history